DNM1L and cardiovascular disorder: Unlike canonical drug-eluting stents that target mTOR or other pathways, PCK1 might be considered a potential target for cardiovascular diseases associated with vascular restenosis on the basis of its unique regulation of the STAT3/DRP1 pathway.